KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Gains from Investment Securities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Gains from Investment Securities for 17 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 93.55% year-over-year to $2.7 million, compared with a TTM value of $56.0 million through Dec 2025, down 24.06%, and an annual FY2025 reading of $56.0 million, down 24.06% over the prior year.
  • Gains from Investment Securities was $2.7 million for Q4 2025 at Biomarin Pharmaceutical, up from $2.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $108.0 million in Q3 2022 and bottomed at -$106.0 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $6.7 million, with a median of $1.2 million recorded in 2022.
  • The sharpest move saw Gains from Investment Securities tumbled 10759.66% in 2022, then soared 11368.77% in 2024.
  • Year by year, Gains from Investment Securities stood at $994000.0 in 2021, then crashed by 10759.66% to -$106.0 million in 2022, then soared by 100.34% to $365000.0 in 2023, then skyrocketed by 11368.77% to $41.9 million in 2024, then crashed by 93.55% to $2.7 million in 2025.
  • Business Quant data shows Gains from Investment Securities for BMRN at $2.7 million in Q4 2025, $2.2 million in Q3 2025, and $49.5 million in Q2 2025.